Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$20.24 -0.6%	$23.71	$12.21 ▼ $40.70	$568.20M	-0.2	758,108 shs	150,102 shs
IOBT IO Biotech	$1.77 -0.3%	$1.69	$0.66 ▼ $2.79	$123.86M	0.44	1.26 million shs	1.30 million shs
KOD Kodiak Sciences	$9.92 +2.2%	$6.05	$1.92 ▼ $11.60	$519.49M	2.41	444,514 shs	266,763 shs
RZLT Rezolute	$6.97 +0.1%	$5.36	$2.21 ▼ $7.15	$604.74M	0.18	920,401 shs	717,686 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+1.04%	+1.95%	-22.32%	-0.39%	-46.11%
IOBT IO Biotech	-5.85%	+38.28%	-9.23%	+46.28%	+12.03%
KOD Kodiak Sciences	+2.21%	-3.29%	+74.01%	+182.27%	+248.03%
RZLT Rezolute	+4.50%	+7.74%	+29.61%	+78.92%	+60.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	3.0484 of 5 stars	4.4	0.0	0.0	2.7	2.5	0.6
IOBT IO Biotech	3.0485 of 5 stars	3.7	3.0	0.0	2.0	2.5	0.6
KOD Kodiak Sciences	3.2361 of 5 stars	2.0	1.0	4.6	2.5	3.3	0.0
RZLT Rezolute	3.2179 of 5 stars	3.6	3.0	0.0	2.6	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$46.13	127.95% Upside
IOBT IO Biotech	3.33	Buy	$8.67	391.03% Upside
KOD Kodiak Sciences	2.00	Hold	$11.75	18.46% Upside
RZLT Rezolute	3.17	Buy	$12.20	75.04% Upside

Current Analyst Ratings Breakdown

Latest IOBT, RZLT, ANAB, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $5.00
8/14/2025	KOD Kodiak Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$4.00 ➝ $7.00
8/14/2025	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$15.00
8/12/2025	ANAB AnaptysBio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $20.00
8/12/2025	IOBT IO Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $4.00
8/7/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $45.00
7/24/2025	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $80.00
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$123.16M	4.60	N/A	N/A	($1.60) per share	-12.65
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$1.33 per share	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.48	N/A	N/A	N/A	-107.66%	-366.98%	-30.58%	11/4/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.58	N/A	N/A	N/A	N/A	-281.82%	-169.29%	N/A
KOD Kodiak Sciences	-$176.21M	-$3.80	N/A	N/A	N/A	N/A	-155.27%	-63.29%	N/A
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)

Latest IOBT, RZLT, ANAB, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/18/2025	Q4 2025	RZLT Rezolute	-$0.22	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	IOBT IO Biotech	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/6/2025	Q2 2025	ANAB AnaptysBio	-$1.50	-$1.34	+$0.16	-$1.34	$11.55 million	$22.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.22	8.22
IOBT IO Biotech	4.22	1.96	2.32
KOD Kodiak Sciences	N/A	3.48	3.48
RZLT Rezolute	N/A	8.43	8.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
IOBT IO Biotech	54.76%
KOD Kodiak Sciences	89.06%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
IOBT IO Biotech	4.80%
KOD Kodiak Sciences	45.90%
RZLT Rezolute	18.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	28.00 million	18.62 million	Optionable
IOBT IO Biotech	30	N/A	N/A	Not Optionable
KOD Kodiak Sciences	90	52.82 million	28.58 million	Optionable
RZLT Rezolute	40	87.00 million	71.00 million	Optionable

IOBT, RZLT, ANAB, and KOD Headlines

Recent News About These Companies

Rezolute appoints Karnawat as Chief Commercial Officer

August 20 at 8:01 PM | msn.com

Rezolute Appoints New Chief Commercial Officer

August 20 at 8:01 PM | msn.com

Rezolute (NASDAQ:RZLT) Hits New 52-Week High - What's Next?

August 20 at 5:14 PM | marketbeat.com

Rezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer to Advance Commercialization of ersodetug

August 20 at 8:11 AM | quiverquant.comQ

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

August 20 at 7:30 AM | globenewswire.com

Altium Capital Management LLC Has $881,000 Position in Rezolute, Inc. (NASDAQ:RZLT)

August 14, 2025 | marketbeat.com

Vivo Capital LLC Sells 685,272 Shares of Rezolute, Inc. (NASDAQ:RZLT)

August 9, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) Given Average Recommendation of "Buy" by Brokerages

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Rezolute Cut by Cantor Fitzgerald

July 28, 2025 | marketbeat.com

Rezolute (NASDAQ:RZLT) Trading 6.5% Higher - Here's Why

July 26, 2025 | marketbeat.com

Cantor Fitzgerald Comments on Rezolute FY2026 Earnings

July 26, 2025 | marketbeat.com

Rezolute (NASDAQ:RZLT) Sets New 52-Week High - Here's What Happened

July 25, 2025 | marketbeat.com

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | globenewswire.com

Rezolute Completes Enrollment for Phase 3 sunRIZE Study

July 18, 2025 | tipranks.com

Rezolute files to sell 1.3M shares of common stock for holders

July 18, 2025 | msn.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of ...

July 10, 2025 | finance.yahoo.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

July 9, 2025 | globenewswire.com

Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 27, 2025 | insidertrades.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

June 25, 2025 | insidertrades.com

Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 24, 2025 | insidertrades.com

Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%

June 3, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOBT, RZLT, ANAB, and KOD Company Descriptions

AnaptysBio NASDAQ:ANAB

$20.24 -0.13 (-0.61%)

As of 03:47 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

IO Biotech NASDAQ:IOBT

$1.76 -0.01 (-0.28%)

As of 03:47 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Kodiak Sciences NASDAQ:KOD

$9.92 +0.21 (+2.15%)

As of 03:48 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Rezolute NASDAQ:RZLT

$6.97 +0.01 (+0.14%)

As of 03:48 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time